OBJECTIVE: The aim of this study was to examine chemotherapy concomitant in vitro activation of human telomerase reverse transcriptase (hTERT)-specific T cell responses in peripheral blood mononuclear cell (PBMC) samples of patients with advanced non-small cell lung cancer (NSCLC). METHODS: PBMCs depleted of regulatory T cells were stimulated by peptide loaded dendritic cells (DC) matured either by application of cytokines (cDC) or a Toll-like receptor 7/8-agonist combined with a soluble CD40-ligand (ligDC). The hTERT peptide-specific T cell responses were assessed using flow cytometry for intracellular interferon-γ (IFN-γ). RESULTS: After cDC activation, T cells producing IFN-γ in response to hTERT were found in PBMC samples of 4 patients. In 2 of these patients the hTERT-specific T cell responses were further increased after ligDC application. However, PBMC of 3 other patients showed little or no induction of hTERT-specific T cell responses as a result of the methods applied during this study. CONCLUSIONS: These results indicate, that concomitant to chemotherapy hTERT-specific T cell responses can be activated in PBMC of NSCLC patients in vitro. This activation can be further increased by ligDC though the number of responding patients is still limited.
OBJECTIVE: The aim of this study was to examine chemotherapy concomitant in vitro activation of human telomerase reverse transcriptase (hTERT)-specific T cell responses in peripheral blood mononuclear cell (PBMC) samples of patients with advanced non-small cell lung cancer (NSCLC). METHODS: PBMCs depleted of regulatory T cells were stimulated by peptide loaded dendritic cells (DC) matured either by application of cytokines (cDC) or a Toll-like receptor 7/8-agonist combined with a soluble CD40-ligand (ligDC). The hTERT peptide-specific T cell responses were assessed using flow cytometry for intracellular interferon-γ (IFN-γ). RESULTS: After cDC activation, T cells producing IFN-γ in response to hTERT were found in PBMC samples of 4 patients. In 2 of these patients the hTERT-specific T cell responses were further increased after ligDC application. However, PBMC of 3 other patients showed little or no induction of hTERT-specific T cell responses as a result of the methods applied during this study. CONCLUSIONS: These results indicate, that concomitant to chemotherapy hTERT-specific T cell responses can be activated in PBMC of NSCLCpatients in vitro. This activation can be further increased by ligDC though the number of responding patients is still limited.
Entities:
Keywords:
Lung cancer; T cells; dendritic cells; telomerase
Authors: Anne Marie Asemissen; Ulrich Keilholz; Stefan Tenzer; Margret Müller; Steffen Walter; Stefan Stevanovic; Hansjörg Schild; Anne Letsch; Eckhard Thiel; Hans-Georg Rammensee; Carmen Scheibenbogen Journal: Clin Cancer Res Date: 2006-12-15 Impact factor: 12.531
Authors: M Meyerson; C M Counter; E N Eaton; L W Ellisen; P Steiner; S D Caddle; L Ziaugra; R L Beijersbergen; M J Davidoff; Q Liu; S Bacchetti; D A Haber; R A Weinberg Journal: Cell Date: 1997-08-22 Impact factor: 41.582
Authors: Christopher Paustian; Richard Caspell; Terrence Johnson; Peter A Cohen; Suyu Shu; Shuwen Xu; Brian J Czerniecki; Gary K Koski Journal: Hum Immunol Date: 2010-10-15 Impact factor: 2.850
Authors: Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou Journal: Nat Med Date: 2004-08-22 Impact factor: 53.440
Authors: Helen Horton; Nina Russell; Erin Moore; Ian Frank; Ruth Baydo; Colin Havenar-Daughton; Deborah Lee; Mark Deers; Michael Hudgens; Kent Weinhold; M Juliana McElrath Journal: J Infect Dis Date: 2004-09-30 Impact factor: 5.226
Authors: Pierre Van Der Bruggen; Yi Zhang; Pascal Chaux; Vincent Stroobant; Christophe Panichelli; Erwin S Schultz; Jacques Chapiro; Benoît J Van Den Eynde; Francis Brasseur; Thierry Boon Journal: Immunol Rev Date: 2002-10 Impact factor: 12.988
Authors: Catherine M Bollard; Laura Aguilar; Karin C Straathof; Benedikt Gahn; M Helen Huls; Alexandra Rousseau; John Sixbey; M Victoria Gresik; George Carrum; Melissa Hudson; Dagmar Dilloo; Adrian Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop Journal: J Exp Med Date: 2004-12-20 Impact factor: 14.307